Article detail · 2021
Recent studies of nitrogen containing heterocyclic compounds as novel antiviral agents: A review
YÖKSİS
OpenAlex
SJR Q2
JCR Q1
Citations 366
Top 1%
Percentile 100.0%
FWCI 23.28
- Year
- 2021
- Type
- article
Data source split
- YÖKSİS YÖKSİS article record
- YÖKSİS venue Bioorganic Chemistry
- Catalog match (ISSN) Bioorganic Chemistry
- OpenAlex OpenAlex enrichment (abstract, citations, topics)
Abstract
Abstract not compiled yet; it will appear after the DergiPark / OpenAlex queue runs.
Topics
Citations
OpenAlex cited_by_count. Not a WoS or Scopus citation count; those sources have no separate column here.
366 citations
OpenAlex cited_by_count (cache / database)
13 publications in the local catalog that cite this work (OpenAlex reference match; not the full global list).
- Recent advances in triazoles as tyrosinase inhibitors 2023
- Synthesis, in vitro, and in silico studies of novel poly‐heterocyclic compounds bearing pyridine and furan moieties as potential anticancer agents 2023
- Imidazole‐thiadiazole hybrids: A multitarget de novo drug design approach, in vitro evaluation, ADME/T, and in silico studies 2024
- Imidazole‐thiadiazole hybrids: A multitarget de novo drug design approach, in vitro evaluation, ADME/T, and in silico studies 2024
- Synthesis, in vitro, and in silico studies of novel poly‐heterocyclic compounds bearing pyridine and furan moieties as potential anticancer agents 2023
- New 1,2,3-triazole-quinazolinone skeleton as potential cholinesterase and α-amylase inhibitors: In vitro and in silico studies 2025
- New 1,2,3-triazole-quinazolinone skeleton as potential cholinesterase and α-amylase inhibitors: In vitro and in silico studies 2025
- New 1,2,3-triazole-quinazolinone skeleton as potential cholinesterase and α-amylase inhibitors: In vitro and in silico studies 2025
- New 1,2,3-triazole-quinazolinone skeleton as potential cholinesterase and α-amylase inhibitors: In vitro and in silico studies 2025
- Design, synthesis, characterization, computational analysis, structure-activity relationship, and investigation of the anticancer potential of novel dibromodibenzoazepine-based hybrid structures 2026